Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.
Taysha Gene Therapies has raised $200.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
Taysha Gene Therapies's investors include Franklin Templeton, RA Capital Management, B Capital, BlackRock, Sands Capital Ventures.
Taysha Gene Therapies is headquartered in Dallas, United States.
Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.
Taysha Gene Therapies is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Taysha Gene Therapies — Funding & Investors." VCBacked, June 24, 2026, https://www.vcbacked.co/company/taysha-gene-therapies. Accessed November 12, 2026.
VCBacked. (2026). Taysha Gene Therapies — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/taysha-gene-therapies
{{cite web |title=Taysha Gene Therapies — Funding & Investors |url=https://www.vcbacked.co/company/taysha-gene-therapies |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Taysha Gene Therapies? Request a listing update